Intermune Inc. has a market cap of $2.47 billion; its shares were traded at around $45.02 with and P/S ratio of 50.7. Intermune Inc. had an annual average earning growth of 2.1% over the past 10 years.ITMN is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC.
This is the annual revenues and earnings per share of ITMN over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of ITMN.
Highlight of Business Operations:Data from the 12-week regimens of the Phase 2b study of un-boosted danoprevir plus SOC were reported on April 14, 2010. Similar virologic response was observed in all danoprevir treatment groups throughout the 12 weeks and after 12 weeks of treatment. At a danoprevir dose of 600 mg twice daily, 86% of patients had levels of HCV RNA below the limit of detection (<LOD) at Week 4 (RVR) and 89% were <LOD at Week 12 (cEVR). At a danoprevir dose of 300 mg three times daily, 73% of patients achieved RVR and 88% achieved cEVR. Viral response of patients at the highest dose of 900 mg twice daily was not meaningfully different from that observed in patients who received 600 mg twice daily or 300 mg three times daily. Analysis of the safety data from the Phase 2b study is preliminary in nature and additional evaluation is ongoing. In the interim safety analysis, serious adverse events (SAEs) were generally balanced across all four treatment groups. The incidence of treatment-emergent Grade 4 (>10x ULN) ALT elevations was 0%, 1%, 6% and 0% in the 300 mg three-times daily, 600 mg twice daily, 900 mg twice daily and placebo groups, respectively. In the danoprevir treatment groups, these elevations occurred generally between weeks 6-8 or later and were reversible after discontinuation of danoprevir. Dosing of the 900 mg arm was stopped based on this safety signal. Treatment-emergent Grade 3 or Grade 4 neutropenia was reported in 24%, 25%, 31% and 16% of patients in the 300 mg three-times daily, 600 mg twice daily, 900 mg twice daily and placebo groups, respectively. The incidence of rash and anemia was comparable across all treatment groups, including the placebo group (SOC + placebo).
Total revenue was $6.1 million and $6.9 million for the three-month periods ended March 31, 2010 and 2009, respectively, representing a decrease of 11%. This decrease was attributable to a continuing decrease in sales of Actimmune of approximately $0.8 million, or 13%. In early March 2008, we announced that our Phase III INSPIRE program for Actimmune in IPF had been discontinued and that future Actimmune revenue was expected to decline. For the three-month periods ended March 31, 2010 and 2009, sales of Actimmune accounted for all of our net product revenue. A majority of this revenue was derived from physicians prescriptions for the off-label use of Actimmune in the treatment of IPF.
Cost of goods sold included product manufacturing costs, royalties, distribution costs and inventory write-downs. Cost of goods sold were $2.6 million and $2.7 million for the three-month periods ended March 31, 2010 and 2009, respectively. The gross margin percentage for our products was 50% and 56% for these periods in 2010 and 2009, respectively. The decline in gross margin percentage reflects the $0.3 million charge we recorded in the first quarter of 2010 related to excess Actimmune inventories. The decline in dollar value of cost of goods sold for the three-months ended March 31, 2010 compared to the same period last year reflects the continuing decline of Actimmune revenue.
Read the The complete Report